Neoantigens, which are tumor-specific antigens derived from nonsynonymous mutations, are very attractive targets for tumor immunotherapy. Thanks to the development of next-generation sequencing technologies and the application of machine learning algorithms, it has become possible to computationally predict neoantigens by characterizing genetic alterations, aberrant post-transcriptional mRNA processing, and aberrant mRNA translation events within tumor tissues. Therefore, neoantigen-based therapies, such as cancer vaccines, have been extensively tested in clinical trials and have demonstrated good safety and efficacy, ushering in a new era for tumor immunotherapy.

Our Services

The research on neoantigen vaccine is an important part of the research on neoantigen targeted therapy, and the production and development of neoantigen vaccine is an important breakthrough in the field of cancer treatment. Alfa Oncology provides the research and development of neoantigen vaccines, include personalized neoantigen vaccines, public neoantigens vaccines and bispecific antibodies related to public neoantigens. Our neoantigen vaccine has a good safety and efficacy profile.

Learn more：neoantigen vaccine